Last updated: April 30, 2024
Sponsor: University of Utah
Overall Status: Active - Recruiting
Phase
1
Condition
Hemodialysis
Kidney Disease
Kidney Failure (Pediatric)
Treatment
Placebo
Empagliflozin
Clinical Study ID
NCT05614115
IRB_00155825
1R01DK131265
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- include diabetic and non-diabetic adults
- dialysis treatment history of ≥3 months
Exclusion
Exclusion Criteria:
- type 1 diabetes
- ongoing intravenous antibiotic therapy for infectious disease
- active treatment for malignancy
- unhealed lower extremity skin ulceration
- history of Fournier's gangrene
- diabetic ketoacidosis
- severe hypoglycemia (requiring external assistance within the past one year)
- allergy to empagliflozin
- pregnancy
Study Design
Total Participants: 75
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 1
Study Start date:
March 21, 2023
Estimated Completion Date:
March 31, 2025
Study Description
Connect with a study center
University of Utah
Salt Lake City, Utah 84132
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.